PET/CT scanning in oligometastatic prostate cancer

Professor Steven Joniau (Urologist, University Hospitals Leuven, Belgium) discusses new developments in the treatment of oligometastatic prostate cancer recurrence, particularly the greater accuracy of PSMA PET/CT over choline PET/CT scanning.

More details...

Understanding treatment resistance in metastatic prostate cancer

In this short video, Gerhardt Attard (Medical Oncologist, The Royal Marsden Hospital, London) discusses his team’s focus at The Institute of Cancer Research on understanding treatment resistance in metastatic prostate cancer and developing tools to allow clinicians to better select treatment for their patients.

More details...

PSA testing in primary care

The Prostate Cancer Risk Management Programme (PCRMP) has recently been updated and aims to help primary care give clear and balanced information to asymptomatic men who ask about testing for prostate cancer. In this short video, Mike Kirby (GP and Visiting Professor to the University of Hertfordshire and …

More details...

‘Innovation in Urology’ day

Each year the RSM Urology Section hosts a programme of scientific events with national and international speakers exploring issues of interest to urologists.
The ‘Innovation in Urology’ day organised by Tom McNicholas and Rik Bryan and sponsored by The Urology Foundation (TUF) on Friday 26 February 2016 …

More details...

A new approach to drug discovery

Chas Bountra (Professor of Translational Medicine and Chief Scientist in the Structural Genomics Consortium at Oxford University) believes that too much competition, duplication and secrecy, both in academia and pharma, mean we are not good at identifying new targets for drug discovery. Here he discusses a …

More details...

What’s new in renal cancer therapy?

Rob Jones (Professor of Clinical Cancer Research, Glasgow University) discusses the new drug treatments being developed for kidney cancer. Until recently there were virtually no effective treatments available for most patients with advanced renal cancer, but the outlook is now much more positive.
Professor Jones was a …

More details...

Bladder cancer: new developments

Nick James (Professor of Oncology at the University of Warwick and Consultant at Queen Elizabeth Hospital, Birmingham) highlights new developments in the treatment of bladder cancer and a new trial that he is setting up (‘Bladder Path’) to investigate the addition of MRI into the haematuria clinic pathway.
Professor …

More details...

STAMPEDE trial results and implications

Nick James (Professor of Oncology at the University of Warwick and Consultant at Queen Elizabeth Hospital, Birmingham) describes the STAMPEDE trial and discusses its implications for the treatment of metastatic prostate cancer.
Professor James was a speaker at the RSM winter meeting in Saalbach, Austria, 16-22 January 2016. Read more about the winter …

More details...

The e-finger project

Alan McNeill, Consultant Urological Surgeon, talks about his ongoing research collaboration with the mechanical engineering department of Heriot Watt University. The prime output of this collaboration has been the development of a fingertip probe that can more accurately assess the mechanical characteristics of the posterior …

More details...

Practical management for patients receiving novel oral hormonal agents for mCRPC

In the video above, Jon Aning (Consultant Urological Surgeon, Newcastle Hospitals NHS Foundation Trust) discusses novel oral hormonal agents for treating metastatic castrate-resistant prostate cancer (mCRPC). He focuses specifically on abiraterone acetate and enzalutamide, highlighting their mechanisms of action, efficacy, common adverse effects and contraindications. This educational …

More details...

Web design and marketing agency Leamington Spa